Author: Crook, Rebecca Lucy; Fathimath Farah, Shiham; Thompson, Elizabeth; Lawrence, A.; Liatsikos, Konstantinos
Title: Journal club Cord-id: 1i2zpp1y Document date: 2021_1_1
ID: 1i2zpp1y
Snippet: If these data are repeated in a phase III trial, the relatively low cost and short duration of treatment could make inhaled budesonide a globally viable treatment option in case management. In the intention-to-treat analysis, the cure rate on day 15 was 77% in the standard duration treatment group (8 days) and 68% in the truncated duration group (3 days), with a between group difference of 9.42% (95% CI −0.38 to 20.04), within the 10% non-inferiority margin. No significant difference was seen
Document: If these data are repeated in a phase III trial, the relatively low cost and short duration of treatment could make inhaled budesonide a globally viable treatment option in case management. In the intention-to-treat analysis, the cure rate on day 15 was 77% in the standard duration treatment group (8 days) and 68% in the truncated duration group (3 days), with a between group difference of 9.42% (95% CI −0.38 to 20.04), within the 10% non-inferiority margin. No significant difference was seen in mortality at day 30 (2% standard, 1% truncated, p>0.99), length of hospital stay (median 5.0 days standard, 6.0 days truncated, p=0.74) or recovery time (median 15.0 days standard, 15.5 days truncated, p=0.33) between the two groups.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date